Co-occurrence of interstitial lung disease and pulmonary embolism as adverse events of adjuvant osimertinib treatment for EGFR mutant non-small cell lung cancer: a case report

Co-occurrence of interstitial lung disease and pulmonary embolism as adverse events of adjuvant osimertinib treatment for EGFR mutant non-small cell lung cancer: a case report

Abstract Background Postoperative osimertinib for EGFR mutant non-small cell lung cancer has become the standard of care. However, its adverse events in clinical practice remain unclear. We report a case of interstitial lung disease and pulmonary embolism occurring simultaneously as adverse events d...

Full description

Saved in:
Bibliographic Details
Main Authors: Kenta Manabe, Kazuhiko Shien, Shinichi Furukawa, Tomoya Seno, Kousei Ishimura, Shin Tanaka, Ken Suzawa, Mikio Okazaki, Seiichiro Sugimoto, Shinichi Toyooka
Format: Article
Language:English
Published: BMC 2025-07-01
Series:BMC Pulmonary Medicine
Subjects:
Osimertinib
Lung cancer
Interstitial lung disease
Pulmonary embolism
Online Access:https://doi.org/10.1186/s12890-025-03787-7
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12890-025-03787-7

Similar Items